Suggested remit: To appraise the clinical and cost effectiveness of tafasitamab plus lenalidomide and rituximab within its marketing authorisation for relapsed or refractory follicular lympho-ma after 1 or more systemic treatments.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6413
Provisional Schedule
- Committee meeting: 1:
- 05 May 2026
- Expected publication:
- 15 July 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
- External Assessment Group:
- Centre for Reviews and Dissemination and Centre for Health Economics, University of York
Stakeholders
- Companies sponsors
- Incyte Biosciences UK (tafasitamab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Blood Cancer UK
- Follicular Lymphoma Foundation
- Lymphoma Action
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- Abbvie (epcoritamab) (confidentiality agreement signed, participating)
- Bristol Myers Squibb (lenalidomide) (confidentiality agreement signed, participating)
- Celltrion Healthcare (rituximab) (confidentiality agreement signed, participating)
- Roche (obinutuzumab, rituximab) (confidentiality agreement signed, participating)
- Advanz Pharma (lenalidomide) (confidentiality agreement not signed, not participating)
- Amarox (lenalidomide) (confidentiality agreement not signed, not participating)
- Biocon Pharma (lenalidomide) (confidentiality agreement not signed, not participating)
- Dr Reddy’s Laboratories (bendamustine) (confidentiality agreement not signed, not participating)
- Grindeks Kalceks UK (lenalidomide) (confidentiality agreement not signed, not participating)
- Mylan (lenalidomide) (confidentiality agreement not signed, not participating)
- Pfizer (rituximab) (confidentiality agreement not signed, not participating)
- Sandoz (lenalidomide, rituximab) (confidentiality agreement not signed, not participating)
- Seacross Pharmaceuticals (bendamustine) (confidentiality agreement not signed, not participating)
- Sun Pharma (lenalidomide) (confidentiality agreement not signed, not participating)
- Teva UK (lenalidomide) (confidentiality agreement not signed, not participating)
- Thornton & Ross (lenalidomide) (confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 September 2025 | Invitation to participate |
| 18 July 2025 - 15 August 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6413 |
| 18 July 2025 | In progress. Scoping commencing |
| 21 December 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 14 December 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual